Evidence for astrocytosis in prodromal alzheimer disease provided by 11C-deuterium-L-deprenyl: A multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG

Journal of Nuclear Medicine

Volumn 53, Issue 1, 2012, Pages 37-46

  Carter, Stephen F ^a   Schöll, Michael ^a   Almkvist, Ove ^a,b   Wall, Anders ^c   Engler, Henry ^c,d   Långström, Bengt ^c,e   Nordberg, Agneta ^a,f  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

^d Uruguayan Centre of Molecular Imaging (CUDIM)   (Uruguay)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer disease; Mild cognitive impairment; Monoamine oxidase B; PET, astrocytosis, amyloid

Indexed keywords

CARBON 11; DEUTERIUM; DEUTERIUM LEVO DEPRENYL C 11; FLUORODEOXYGLUCOSE F 18; PITTSBURGH COMPOUND B; SELEGILINE; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; ANATOMICAL VARIATION; ARTICLE; ASTROCYTOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMALE; FRONTAL CORTEX; GRAY MATTER; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGE PROCESSING; MALE; MINI MENTAL STATE EXAMINATION; OUTCOME ASSESSMENT; PARIETAL CORTEX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BENZOTHIAZOLES; BRAIN; CASE-CONTROL STUDIES; DEUTERIUM; FEMALE; FLUORODEOXYGLUCOSE F18; GLIOSIS; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; MONOAMINE OXIDASE; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RETROSPECTIVE STUDIES; SELEGILINE;

EID: 84855369203     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.087031     Document Type: Article

References (39)

1. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297:353-356. (Pubitemid 34790756)
2. Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol. 2010;6:193-201.
3. Verkhratsky A, Olabarria M, Noristani HN, Yeh CY, Rodriguez JJ. Astrocytes in Alzheimer's disease. Neurotherapeutics. 2010;7:399-412.
4. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55:306-319. (Pubitemid 38269583)
5. Cagnin A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. Lancet. 2001;358:461-467. (Pubitemid 32769854)
6. 11C]PIB-PET study. Neurobiol Dis. 2008;32:412-419.
7. Okello A, Edison P, Archer HA, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology. 2009;72:56-62.
8. Wiley CA, Lopresti BJ, Venneti S, et al. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol. 2009;66:60-67.
9. Fowler JS, Logan J, Volkow ND, Wang GJ. Translational neuroimaging: positron emission tomography studies of monoamine oxidase. Mol Imaging Biol. 2005;7:377-387. (Pubitemid 44193402)
10. Saura J, Bleuel Z, Ulrich J, et al. Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry. Neuroscience. 1996;70:755-774. (Pubitemid 26009057)
11. 11C-labeled suicide inactivators and PET. Science. 1987;235:481-485.
12. Fowler JS, Volkow ND, Wang GJ, et al. Age-related increases in brain monoamine oxidase B in living healthy human subjects. Neurobiol Aging. 1997;18:431-435. (Pubitemid 27435085)
13. Engler H, Lundberg PO, Ekbom K, et al. Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease. Eur J Nucl Med Mol Imaging. 2003;30:85-95. (Pubitemid 36692897)
14. 11C](L)-deprenyl-D2 PET. J Neurol Sci. 2007;255:17-22.
15. 18F-FDG in focal epilepsy. Acta Neurol Scand. 2001;103:360-366.
16. 11C-L-deuterium- deprenyl-analysis of kinetic data. Acta Neurol Scand. 1998;98:224-231.
17. 11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301. Clin Pharmacol Ther. 2009;85:506-512.
18. Saura J, Luque JM, Cesura AM, et al. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience. 1994;62:15-30. (Pubitemid 24287342)
19. Yu WF, Guan ZZ, Bogdanovic N, Nordberg A. High selective expression of alpha7 nicotinic receptors on astrocytes in the brains of patients with sporadic Alzheimer's disease and patients carrying Swedish APP 670/671 mutation: a possible association with neuritic plaques. Exp Neurol. 2005;192:215-225. (Pubitemid 40208555)
20. 11C]-L-deprenyl using whole hemisphere autoradiography. Neurochem Int. 2011;58:60-68.
21. Kadir A, Marutle A, Gonzalez D, et al. Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease. Brain. 2011;134: 301-317.
22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944. (Pubitemid 14076461)
23. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183-194. (Pubitemid 39222988)
24. Bergman I, Blomberg M, Almkvist O. The importance of impaired physical health and age in normal cognitive aging. Scand J Psychol. 2007;48:115-125.
25. Ashburner J, Friston KJ. Unified segmentation. Neuroimage. 2005;26:839-851. (Pubitemid 40825026)
26. Hammers A, Allom R, Koepp MJ, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Hum Brain Mapp. 2003;19:224-247. (Pubitemid 36959351)
27. Fowler JS, Volkow ND, Logan J, et al. Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327. Neurology. 1993;43:1984-1992. (Pubitemid 23318865)
28. Nordberg A, Rinne J, Drzezga A, et al. PETAmyloid imaging and cognition in patients with Alzheimer's disease, mild cognitive impairment (MCI) and healthy controls: a European multicenter study. Alzheimer's & Dementia. 2009;5:P2.
29. Anchisi D, Borroni B, Franceschi M, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol. 2005;62:1728-1733. (Pubitemid 41626670)
30. Edison P, Archer HA, Hinz R, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007; 68:501-508.
31. Kemppainen NM, Aalto S, Wilson IA, et al. Voxel-based analysis of PET amyloid ligand [11C]PIB uptake in Alzheimer disease. Neurology. 2006;67:1575-1580. (Pubitemid 44747926)
32. 11C-PIB PET study. Neurology. 2009;73:754-760.
33. Lichtenstein MP, Carriba P, Masgrau R, Pujol A, Galea E. Staging anti-inflammatory therapy in Alzheimer's disease. Frontiers in Aging Neurosci. 2010;2:1-6.
34. Liem RK, Messing A. Dysfunctions of neuronal and glial intermediate filaments in disease. J Clin Invest. 2009;119:1814-1824.
35. Johnson KA, Mueller ST, Walshe TM, English RJ, Holman BL. Cerebral perfusion imaging in Alzheimer's disease: use of single photon emission computed tomography and iofetamine hydrochloride I 123. Arch Neurol. 1987;44: 165-168. (Pubitemid 17002599)
36. Powers WJ, Perlmutter JS, Videen TO, et al. Blinded clinical evaluation of positron emission tomography for diagnosis of probable Alzheimer's disease. Neurology. 1992;42:765-770.
37. Yoshiura T, Hiwatashi A, Noguchi T, et al. Arterial spin labelling at 3-T MR imaging for detection of individuals with Alzheimer's disease. Eur Radiol. 2009;19:9-11.
38. Bartenstein P, Minoshima S, Hirsch C, et al. Quantitative assessment of cerebral blood flow in patients with Alzheimer's disease by SPECT. J Nucl Med. 1997;38:1095-1101. (Pubitemid 27339617)
39. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131:1630-1645. (Pubitemid 351806448)